Baird Updates Intellia Therapeutics, Inc. (NTLA)’s Financial Model Following Nex-Z Clinical Hold Removal

TheFly reported connected January 28 that Baird raised its terms people connected NTLA to $7 from $4 while maintaining a Neutral rating. The steadfast updated its exemplary pursuing the FDA’s lifting of the objective clasp connected the Nex-z hATTR-PN trial.

Similarly, connected the aforesaid day, H.C. Wainwright expert Mitchell Kapoor besides raised the terms people connected Intellia Therapeutics, Inc. (NASDAQ:NTLA) to $25 from $15 and maintained a Buy rating. The steadfast noted that the FDA’s determination to assistance the objective clasp indicates Nex-Z’s risks are manageable, though the marketplace continues to terms successful “an existential threat,” and besides accrued its probability of support for Nex-Z to 35% from 25%.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is simply a clinical‑stage biotechnology institution pioneering CRISPR‑based cistron editing therapies to dainty superior familial diseases. The institution uses its proprietary successful vivo and ex vivo platforms and develops precision treatments aimed astatine providing durable, curative solutions, advancing aggregate programs toward objective interaction portion expanding the imaginable of cistron editing.

While we admit the imaginable of NTLA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.